• Corpus ID: 24670351

[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].

@article{1984PhaseIS,
  title={[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].},
  author={},
  journal={Gan to kagaku ryoho. Cancer \& chemotherapy},
  year={1984},
  volume={11 1},
  pages={
          143-9
        }
}
  • Published 1984
  • Medicine
  • Gan to kagaku ryoho. Cancer & chemotherapy
A phase I study of a new floxuridine derivative, FF-705, was performed in patients with various types of solid tumors. Efficacy of single oral administration with dose range of 300 to 700 mg/body was studied in 12 patients. At a dose of 500 mg/body transient increases of s GOT and s GPT were noted in one patient and, of 700 mg/body, nausea, vomiting or stomach dullness sensation was noted in two patients. The maximum tolerated dose was considered to be 700 mg/body or more. The dose limiting…